Placebo washout in trials of antipsychotic drugs

Schizophrenia Bulletin

Volumn 22, Issue 4, 1996, Pages 567-576

  Volavka, Jan ^a,b,c   Cooper, Thomas B ^c,d,e   Laska, Eugene M ^b,f   Meisner, Morris ^f  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b Nathan S Kline Inst Psychiat Res   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUPHENAZINE DECANOATE; HALOPERIDOL; HOMOVANILLIC ACID; NEUROLEPTIC AGENT; PLACEBO; STREET DRUG;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; DYSKINESIA; HUMAN; META ANALYSIS; MOTOR DYSFUNCTION; ORAL DRUG ADMINISTRATION; PARKINSONISM; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCHIZOPHRENIA; TREATMENT OUTCOME; TREMOR; WITHDRAWAL SYNDROME;

EID: 0029909537     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/schbul/22.4.567     Document Type: Review

References (46)

1. Addington, D. The use of placebos in clinical trials for acute schizophrenia. Canadian Journal of Psychiatry, 40:171-176, 1995.
2. American Psychiatric Association. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: The Association, 1994.
3. Baldessarini, R.J., and Viguera, A.C. Neuroleptic withdrawal in schizophrenic patients. Archives of General Psychiatry, 52:189-192, 1995.
4. Branchey, M.H.; Branchey, L.B.; and Richardson, M.A. Effects of neuroleptic adjustment on clinical condition and tardive dyskinesia in schizophrenic patients. American Journal of Psychiatry, 138:608-612, 1981.
5. Brittain, E., and Wittes, J. The run-in period in clinical trials: The effect of misclassification on efficiency. Controlled Clinical Trials, 11:327-338, 1990.
6. Campbell, A., and Baldessarini, R.J. Prolonged pharmacologic activity of neuroleptics. [Letter] Archives of General Psychiatry, 42:637, 1985.
7. Chouinard, G. Severe cases of neuroleptic-induced supersensitivity psychosis: Diagnostic criteria for the disorder and its treatment. Schizophrenia Research, 5:21-33, 1990.
8. Chouinard, G.; Jones, B.; Remington, G.; Bloom, D.; Addington, D.; MacEwan, G.W.; Labelle, A.; Beauclair, L.; and Arnott, W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology, 13:25-40, 1993.
9. Cohen, B.M.; Babb, S.; Campbell, A.; and Baldessarini, R.J. Persistence of haloperidol in the brain. Archives of General Psychiatry, 45:879-880, 1988.
10. Cole, J.O.; Klerman, G.L.; and Goldberg, S.C. Phenothiazine treatment in acute schizophrenia. Archives of General Psychiatry, 10:246-261, 1964.
11. Davidson, M.; Kahn, R.S.; Powchik, P.; Warne, P.; Losonczy, M.E; Kaminsky, R.; Apter, S.; Jaff, S.; and Davis, K.L. Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation. Archives of General Psychiatry, 48:73-76, 1991.
12. Davis, C.E.; Applegate, W.B.; Gordon, D.J.; Curtis, R.C.; and McCormick, M. An empirical evaluation of the placebo run-in. Controlled Clinical Trials, 16:41-50, 1995.
13. Gallant, D.M.; Bishop, M.P.; Free, S.M., Jr.; Goldberg, S.C.; and Simpson, G.M. Evaluation of efficacy of psychotropic agents in schizophrenic populations: Methodological procedures. In: Levine, J.; Schiele, B.C.; and Bouthilet, L., eds. Principles and Problems in Establishing the Efficacy of Psychotropic Agents. Washington, DC: U.S. Department of Health, Education, and Welfare, 1971. pp. 59-90.
14. Gershon, S.; Hekimian, L.J.; Burdock, E.I.; and Kim, S.S. Antipsychotic properties of loxapine succinate. Current Therapeutic Research, 12:280-285, 1970.
15. Goldberg, S.C.; Frosch, W.A.; Drossman, A.K.; Schooler, N.R.; and Johnson, G.F.S. Prediction of response to phenothiazines in schizophrenia: A crossvalidation study. Archives of General Psychiatry, 26:367-373, 1972.
16. Goldberg, S.C.; Mattsson, N.; Cole, J.O.; and Klerman, G.L. Prediction of improvement in schizophrenia under four phenothiazines. Archives of General Psychiatry, 16:107-117, 1967.
17. Hirsch, S.R., and Barnes, T.R.E. Testing the efficacy of new neuroleptic drugs. In: Benkert, O.; Maier, W.; and Rickels, K., eds. Methodology of the Evaluation of Psychotropic Drugs. Psychopharmacology Series 8. Berlin, Germany: Springer-Verlag, 1990. pp. 26-36.
18. Hubbard, J.W,; Ganes, D.; and Midha, K.K. Prolonged pharmacologic activity of neuroleptic drugs. [Letter] Archives of General Psychiatry, 44:99-100, 1987.
19. Jones, M.B., and Ainslie, J.D. Value of a placebo wash-out. Diseases of the Nervous System, 27:393-396, 1966.
20. Kane, J.; Honigfeld, G.; Singer, J.; Meltzer, H.; and the Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45:789-796, 1988.
21. Kane, J.M.; Schooler, N.R.; Marder, S.R.; Simpson, G.M.; and Casey, D.E. Methods for clinical evaluation of pharmacologic treatments of schizophrenia. In: Prien, R.R, and Robinson, D.S., eds. Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines. New York, NY: Raven Press, 1994. pp. 345-372.
22. Klawans, H.L., Jr.; Bergen, D.; and Bruyn, G.W. Prolonged drug-induced parkinsonism. Confinia Neurologica, 35:368-377, 1973.
23. Kraepelin, E. Dementia Praecox and Paraphrenia. (1919) Translated by R.M. Barkley. Huntington, NY: Robert E. Krieger Publishing Company, 1961.
24. Laska, E.M.; Klein, D.F.; Lavori, P.W.; Levine, J.; and Robinson, D.S. Design issues for the clinical evaluation of psychotropic drugs. In: Prien, R.F., and Robinson, D.S., eds. Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines. New York, NY: Raven Press, 1994. pp. 29-67.
25. Libiger, J.; Czobor, P.; and Volavka, J. Does the change of psychopathology during the placebo period predict the response to subsequent treatment with active medication? Psychiatry Research, 52:107-114, 1994a.
26. Libiger, J.; Czobor, P.; and Volavka, J. Does the change of psychopathology during the placebo period predict the response to subsequent treatment with active medication? Correction. [Letter] Psychiatry Research, 53:218, 1994b.
27. Marder, S.R., and Meibach, R.C. Risperidone in the treatment of schizophrenia. American Journal of Psychiatry, 151:825-835, 1994.
28. McEvoy, J.P.; Hogarty, G.E.; and Steingard, S. Optimal dose of neuroleptic in acute schizophrenia. Archives of General Psychiatry, 48:739-745, 1991.
29. Overall, J.E., and Gorham, D.R. The Brief Psychiatric Rating Scale. Psychological Reports, 10:799-812, 1962.
30. Palao, D.J.; Arauxo, A.; Brunet, M.; Bernardo, M.; Haro, J.M.; Ferrer, J.; and Gonzalez-Monclus, E. Haloperidol: Therapeutic window in schizophrenia. Journal of Clinical Psychopharmacology, 14:303-310, 1994.
31. Peuskens, J. Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. British Journal of Psychiatry, 166:712-726, 1995.
32. Pickar, D.; Labarca, R.; Doran, A.R.; Wolkowitz, O.M.; Roy, A.; Breier, A.; Linnoila, M.; and Paul, S.M. Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients: Correlation with psychosis and response to neuroleptic treatment. Archives of General Psychiatry, 43:669-676, 1986.
33. Potkin, S.G.; Shen, Y.; Zhou, D.; Pardes, H.; Shu, L.; Phelps, B.; and Poland, R.E. Does a therapeutic window for plasma haloperidol exist? Preliminary Chinese data. Psychopharmacology Bulletin, 21(1):59-61, 1985.
34. Prien, R.F. Methods and models for placebo use in pharmacotherapeutic trials. Psychopharmacology Bulletin, 24(1):4-8, 1988.
35. Sampath, G.; Shah, A.; Krska, J.; and Soni, S.D. Neuroleptic discontinuation in the very stable schizophrenic patient: Relapse rates and serum neuroleptic levels. Human Psychopharmacology, 7:255-264, 1992.
36. Santos, J.L.; Cabranes, J.A.; Almoguera, I.; Ramos, J.A.; Vazquez, C.; and Angeles, F. Clinical implications of determination of plasma haloperidol levels. Acta Psychiatrica Scandinavica, 79:348-354, 1989.
37. Schechtman, K.B., and Gordon, M.E. A comprehensive algorithm for determining whether a run-in strategy will be a cost-effective design modification in a randomized clinical trial. Statistics in Medicine, 12:111-128, 1993.
38. Shopsin, B.; Klein, H.; Aaronsom, M.; and Collora, M. Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients: A controlled, double-blind comparison. Archives of General Psychiatry, 36:657-664, 1979.
39. Shopsin, B.; Pearson, E.; Gershon, S.; and Collins, P. A controlled double-blind comparison between loxapine succinate and chlorpromazine in acute newly hospitalized schizophrenic patients. Current Therapeutic Research, 14:739-748, 1972.
40. Trivedi, M.H., and Rush, J. Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications? Neuropsychopharmacology, 11:33-43, 1994.
41. Van Putten, T.; Marder, S.R.; Mintz, J.; and Poland, R.E. Haloperidol plasma levels and clinical response: A therapeutic window relationship. American Journal of Psychiatry, 149:500-505, 1992.
42. Volavka, J. Lead-in placebo washout period. [Letter] British Journal of Psychiatry, 167:694, 1995a.
43. Volavka, J. Placebo reconsidered. [Letter] Canadian Journal of Psychiatry, 40:426-427, 1995b.
44. Volavka, J.; Cooper, T.B.; Czobor, P.; Bitter, I.; Meisner, M.; Laska, E.; Gastanaga, P.; Krakowski, M.; Chou, C.J.-Y; Crowner, M.; and Douyon, R. Haloperidol blood levels and clinical effects. Archives of General Psychiatry, 49(5):354-361, 1992.
45. Volavka, J.; Cooper, T.B.; Czobor, P.; and Meisner, M. Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder. Archives of General Psychiatry, 52:837-845, 1995.
46. Wittenborn, J.R. Guidelines for clinical trials in psychopharmacology. In: Lipton, M.A.; DiMascio, A.; and Killam, K.F., eds. Psychopharmacology. A Generation of Progress. New York, NY: Raven Press, 1978. pp. 833-840.